Comparison of Yttrium-90 Radioembolization and Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma

Journal of Vascular and Interventional Radiology

Volumn 21, Issue 2, 2010, Pages 224-230

  Kooby, David A ^a   Egnatashvili, Vasili ^a   Srinivasan, Swetha ^a   Chamsuddin, Abbas ^a   Delman, Keith A ^a   Kauh, John ^b   Staley III, Charles A ^a   Kim, Hyun S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN; CISPLATIN; DOXORUBICIN; MACROSALB TC 99M; MITOMYCIN; MITOMYCIN C; RADIOACTIVE MICROSPHERE; YTTRIUM 90;

ABDOMINAL PAIN; ADULT; ARTERIOVENOUS SHUNT; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; COIL EMBOLIZATION; COMPARATIVE TOXICOLOGY; CRYOABLATION; DIGESTIVE SYSTEM ULCER; DISEASE COURSE; FEMALE; GASTRITIS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEPATIC ENCEPHALOPATHY; HEPATITIS C VIRUS; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; INOPERABLE CANCER; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER METASTASIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY SHUNT; RADIATION DOSE; RADIATION RESPONSE; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; SOLID TUMOR; THERAPY EFFECT; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING;

AGED; CARCINOMA, HEPATOCELLULAR; CATHETERIZATION, PERIPHERAL; CHEMOEMBOLIZATION, THERAPEUTIC; DATABASES AS TOPIC; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PILOT PROJECTS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 74449092429     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvir.2009.10.013     Document Type: Article

References (32)

1. Bruix J., Cirera I., Calvet X., et al. Surgical resection and survival in Western patients with hepatocellular carcinoma. J Hepatol 15 (1992) 350-355
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
3. Llovet J.M., Fuster J., and Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30 (1999) 1434-1440
4. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
5. Fong Y., Sun R.L., Jarnagin W., and Blumgart L. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 229 (1999) 790-799
6. Marcos-Alvarez A., Jenkins R.L., Washburn W.K., et al. Multimodality treatment of hepatocellular carcinoma in a hepatobiliary specialty center. Arch Surg 131 (1996) 292-298
7. Kooby D.A., Egnatashvili V., Graiser M., et al. Changing management and outcome of hepatocellular carcinoma: evaluation of 501 patients treated at a single comprehensive center. J Surg Oncol 98 (2008) 81-88
8. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35 (2002) 1164-1171
9. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359 (2002) 1734-1739
10. Camma C., Schepis F., Orlando A., et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224 (2002) 47-54
11. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003) 429-442
12. Simonetti R.G., Liberati A., Angiolini C., and Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 8 (1997) 117-136
13. Popperl G., Helmberger T., Munzing W., Schmid R., Jacobs T.F., and Tatsch K. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. Cancer Biother Radiopharm 20 (2005) 200-208
14. Lim L., Gibbs P., Yip D., et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J 35 (2005) 222-227
15. Lau W.Y., Ho S., Leung T.W., et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40 (1998) 583-592
16. Burton M.A., Gray B.N., Klemp P.F., Kelleher D.K., and Hardy N. Selective internal radiation therapy: distribution of radiation in the liver. Eur J Cancer Clin Oncol 25 (1989) 1487-1491
17. Ibrahim S.M., Lewandowski R.J., Ryu R.K., et al. Radiographic response to yttrium-90 radioembolization in anterior versus posterior liver segments. Cardiovasc Intervent Radiol 31 (2008) 1124-1132
18. Kulik L.M., Carr B.I., Mulcahy M.F., et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47 (2008) 71-81
19. Salem R., Parikh P., Atassi B., et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 31 (2008) 431-438
20. Bester L., and Salem R. Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization. J Vasc Interv Radiol 18 (2007) 1310-1314
21. Salem R., and Thurston K.G. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. I. Technical and methodologic considerations. J Vasc Interv Radiol 17 (2006) 1251-1278
22. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33 (2001) 464-470
23. Trotti A., Colevas A.D., Setser A., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13 (2003) 176-181
24. Carr B.I. Hepatic arterial 90yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transplantation 10 (2004) S107-S110
25. Ariel I.M., and Padula G. Treatment of symptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes. J Surg Oncol 10 (1978) 327-336
26. Grady E.D. Internal radiation therapy of hepatic cancer. Dis Colon Rectum 22 (1979) 371-375
27. Houle S. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology 172 (1989) 857-860
28. Shepherd F.A., Rotstein L.E., Houle S., Yip T.C., Paul K., and Sniderman K.W. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 70 (1992) 2250-2254
29. Gray B.N. Tolerance of the liver to the effects of yttrium-90 radiation. Int J Radiat Oncol Biol Phys 18 (1990) 619-623
30. Gray B., Van Hazel G., Hope M., et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12 (2001) 1711-1720
31. Rosler H., Triller J., Baer H.U., et al. Superselective radioembolization of hepatocellular carcinoma: 5-year results of a prospective study. Nucl Med (Stuttg) 33 (1994) 206-214
32. Salem R., Lewandowski R.J., Atassi B., et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16 (2005) 1627-1639